Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAU-SED vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Mild to moderate hypertension,Management of psychotic disorders (off-label)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
250 mg orally twice daily
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Extensively metabolized in the liver via ester hydrolysis; major metabolite is trimethoxybenzoic acid; not fully characterized in humans.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
96% bound, primarily to albumin and alpha-1-acid glycoprotein
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
8-10 L/kg; clinical meaning: extensive tissue distribution, high affinity for adipose tissue and brain
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 40-50% (first-pass metabolism); Intramuscular: 100% (complete absorption)
70-90% (oral); 100% (IV).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-60 m L/min), reduce dose by 50%. No adjustment needed for Cr Cl >60 m L/min.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Contraindicated in severe hepatic impairment (Child-Pugh Class C). For moderate impairment (Child-Pugh Class B), reduce dose by 50% and monitor for excessive sedation. No adjustment for mild (Child-Pugh Class A).
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended due to lack of safety and efficacy data. Avoid use in children.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate with 0.1 mg orally once daily; titrate slowly based on response and tolerability. Monitor for orthostatic hypotension and sedation.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
Reserpine may increase the risk of suicide; patients should be monitored for depression. It should not be used in patients with a history of mental depression.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause severe depression, especially in patients with psychiatric history; may cause bradycardia, electrolyte imbalance, and gastrointestinal effects; caution in patients with peptic ulcer disease or gallstones due to increased gastric acid secretion.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
History of mental depression (especially suicidal tendencies), active peptic ulcer, ulcerative colitis, concurrent electroconvulsive therapy (ECT), hypersensitivity to reserpine or rauwolfia alkaloids.
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce) as rauwolfia alkaloids can potentiate hypertensive crises. Limit caffeine intake. High-fiber diets may reduce absorption separate doses.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Reserpine crosses placenta. First trimester: Increased risk of congenital malformations (cardiac defects, CNS anomalies) in animal studies; human data limited but risk considered elevated. Second/third trimesters: Risk of neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to catecholamine depletion. Avoid use throughout pregnancy unless essential.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Reserpine is excreted into breast milk. M/P ratio not reported. Potential for infant effects: nasal congestion, bradycardia, hypotonia. Use is contraindicated due to possible severe adverse effects in the nursing infant.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Dose should be kept as low as possible. Due to increased plasma volume in pregnancy, monitor clinical response; no specific dose adjustment recommendations. Consider alternative antihypertensives with better safety profile.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
RAU-SED (rauwolfia serpentina) is an antihypertensive and antipsychotic alkaloid. Onset of action is slow (2-3 weeks) for hypertension. Monitor for bradycardia, nasal congestion, and depression. Do not use with MAOIs or electroconvulsive therapy. Taper to avoid withdrawal hypertension.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not stop suddenly as this may cause severe hypertension.,May cause drowsiness, dizziness, or nasal congestion; avoid driving if affected.,Report signs of depression, nightmares, or extrapyramidal symptoms (muscle stiffness, tremors).,Avoid alcohol and over-the-counter cold medications containing decongestants.,Rise slowly from sitting or lying to minimize postural hypotension.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAU-SED vs ALDOCLOR-250, answered by our medical review team.
RAU-SED is a Antihypertensive that works by Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAU-SED and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAU-SED is: Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAU-SED and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAU-SED is classified as Category C. Reserpine crosses placenta. First trimester: Increased risk of congenital malformations (cardiac defects, CNS anomalies) in animal studies; human data limited but risk considered e. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.